Mayliu Biotech

Mayliu Biotech is a materials innovation company specializing in synthetic biology to develop high-value bioactive substances, including recombinant collagen and active peptides. The company has established the Mayliu-Technology Platform, which utilizes engineered Pichia pastoris strains and machine learning-driven optimization for the efficient secretory expression of proteins. By integrating R&D, pilot-scale trials, and large-scale manufacturing, the company has achieved technological breakthroughs, such as producing recombinant human-derived Type III collagen with high purity at significantly reduced production costs compared to traditional market standards.

These advancements address critical industry needs by providing cost-effective, high-quality ingredients for applications in medical aesthetics, skincare, biopharmaceuticals, and other health-related sectors. By solving supply chain price barriers, Mayliu Biotech enables broader access to high-performance biological materials. The company collaborates with leading research institutions to support industrialization and has developed a diverse portfolio of over 50 products spanning consumer goods, medicine, and industrial materials. Their commitment to innovation and full-chain production capabilities positions them as a key player in the synthetic biology industry.